Prospective study of the severity-based treatment protocol for Japanese patients with MPO-ANCA-associated vasculitis

Prospective study of the severity-based treatment protocol for Japanese patients with MPO-ANCA-associated vasculitis - JMAAV

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000867

Enrollment

Registered

2007-10-30

Start date

2004-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MPO-ANCA-associated vasculitis

Interventions

IVCY0.5-0.75g/m2 or oral CY 0.5-2.0mg/kg/day plus prednisolone 0.6-1.0mg/kg/day for the severe cases. Add plasma exchange for the most severe cases. Omit cyclophosphamide for aged cases with RPGN

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: MPO-ANCA positive and one of the following criteria determined by the Research Committees of Japanese ministry of Health, Labor and Welfare. 1. criteria for microscopic polyangiitis 2. criteria for polyarteritis nodosa 3. rapidly progressive glomerulonephritis

Exclusion criteria

Exclusion criteria: 1. age over 80 2. active infection 3. WBC<4000 4. Platelt < 120,000 5. chronic dialysis 6. severe respiratory failure 7. liver cirrhosis 8. malignancy within 5 years 9. pregnancy 10. previous cumulative cyclophosphamide dosage > 10g

Design outcomes

Primary

Measure	Time frame
remission induction, permanent renal failure and death	—

Secondary

Measure	Time frame
BVAS, VDI, SF-36, adverse effects	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026